

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/014005-2021>

Opportunity

## **NHS National Generic Pharmaceuticals Wave 13**

The NHS Commissioning Board (operating under the name of NHS England)

F02: Contract notice

Notice reference: 2021/S 000-014005

Published: 21 June 2021, 11:23am

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

The NHS Commissioning Board (operating under the name of NHS England)

2nd Floor, Rutland House

Runcorn

WA7 2ES

#### **Contact**

Gemma Tomlinson/Lynne Tierney

#### **Email**

[gemma.tomlinson1@nhs.net](mailto:gemma.tomlinson1@nhs.net)

#### **Country**

United Kingdom

#### **NUTS code**

UK - United Kingdom

### **Internet address(es)**

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

### **I.2) Information about joint procurement**

The contract is awarded by a central purchasing body

### **I.3) Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at

<http://health.atamis.co.uk>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<http://health.atamis.co.uk>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<http://health.atamis.co.uk>

### **I.4) Type of the contracting authority**

Ministry or any other national or federal authority

### **I.5) Main activity**

Health

---

## Section II: Object

### II.1) Scope of the procurement

#### II.1.1) Title

NHS National Generic Pharmaceuticals Wave 13

Reference number

CM/PHG/17/5532

#### II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

#### II.1.3) Type of contract

Supplies

#### II.1.4) Short description

Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months)

#### II.1.5) Estimated total value

Value excluding VAT: £1,637,875,080

#### II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

## **II.2) Description**

### **II.2.1) Title**

Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)

Lot No

1

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to document 03, schedule 8 in the ITO documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months)

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

## **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months

19

This contract is subject to renewal

No

## **II.2.10) Information about variants**

Variants will be accepted: No

## **II.2.11) Information about options**

Options: Yes

Description of options

Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

## **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

Lot No

2

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

Main site or place of performance

Please refer to document 03, schedule 8 in the ITO documents for the list of Purchasing Points

### **II.2.4) Description of the procurement**

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13  
Offer reference number: CM/PHG/17/5532  
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.  
Potential periods of call-offs under the framework agreement: Transition (Everolimus)  
CESW: 1 March 2022 – 30 September 2023 (19 months)  
LSNE: 1 March 2022 – 31 January 2023 (11 months)  
NWLN: 1 March 2022 – 31 January 2023 (11 months)  
Oral Products plus non-parenterals  
All Regions: 1 March 2022 - 31 May 2024 (27 months)  
Hospital Only Products  
CESW: 1 February 2022 – 30 September 2023 (20 months)  
LSNE: 1 February 2022 – 31 May 2024 (28 months)  
NWLN: 1 February 2022 – 31 January 2023 (12 months)

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months

27

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Lot 3 - CM/PHG/17/5532/02 Hospital Only Products

Lot No

3

### **II.2.2) Additional CPV code(s)**

- 33600000 - Pharmaceutical products

### **II.2.3) Place of performance**

NUTS codes

- UK - United Kingdom

### **II.2.4) Description of the procurement**

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral

Products plus non-parenteralsAll Regions: 1 March 2022 - 31 May 2024 (27 months)Hospital  
Only ProductsCESW: 1 February 2022 – 30 September 2023 (20 months)LSNE: 1 February  
2022 – 31 May 2024 (28 months)NWLN: 1 February 2022 – 31 January 2023 (12 months)

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months

28

This contract is subject to renewal

No

### **II.2.10) Information about variants**

Variants will be accepted: No

### **II.2.11) Information about options**

Options: Yes

Description of options

Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No



---

## **Section III. Legal, economic, financial and technical information**

### **III.1) Conditions for participation**

#### **III.1.2) Economic and financial standing**

Selection criteria as stated in the procurement documents

### **III.2) Conditions related to the contract**

#### **III.2.2) Contract performance conditions**

See KPIs in procurement documents

---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.1) Type of procedure**

Open procedure

#### **IV.1.3) Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: Yes

### **IV.2) Administrative information**

#### **IV.2.2) Time limit for receipt of tenders or requests to participate**

Date

26 July 2021

Local time

1:00pm

**IV.2.4) Languages in which tenders or requests to participate may be submitted**

English

**IV.2.6) Minimum time frame during which the tenderer must maintain the tender**

Duration in months: 3 (from the date stated for receipt of tender)

**IV.2.7) Conditions for opening of tenders**

Date

26 July 2021

Local time

1:00pm

Place

Runcorn

Information about authorised persons and opening procedure

Commercial Medicines Unit Employee

## Section VI. Complementary information

### VI.1) Information about recurrence

This is a recurrent procurement: No

### VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

### VI.3) Additional information

RESPONDING TO THIS NOTICE; Any supplier may be disqualified who does not respond to the following in the requisite manner: 1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at <http://health.atamis.co.uk> Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows: 1.1) If not already registered, Candidates should register on the eTendering portal at <http://health.atamis.co.uk> and click the link to register:- agree to the user agreement- populate company details 1.2) Once registered, candidates must register interest as follows:- log to the portal- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select- review opportunity details and click "Register Interest"- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity) 1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis helpdesk at [supporthealth@atamis.co.uk](mailto:supporthealth@atamis.co.uk) or by calling 0800 9956035 for technical assistance when completing responses. 2) General supplier information. To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows: 2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page <https://supplierregistration.cabinetoffice.gov.uk> and select "Register" at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system. 2.2) Once registration is complete you are able to create and update your company

profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B.2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the message function on the website. OTHER CONTRACTING AUTHORITIES The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

## **VI.4) Procedures for review**

### **VI.4.1) Review body**

The High Court

Strand

London

WC2A 2LL

Email

[generaloffice@administrativecourtoffice.justice.gov.uk](mailto:generaloffice@administrativecourtoffice.justice.gov.uk)

Country

United Kingdom

Internet address

<https://www.gov.uk/courts-tribunals>